Assessing the impact of HBV NAT on window period reduction and residual risk.
about
Comparison of epidemiological methods for estimation of hepatitis B incidence and residual risk for blood donors in southern BrazilThe estimation of prevalence, incidence, and residual risk of transfusion-transmitted human hepatitis B infection from blood donated at the Anhui blood center, China, from 2009 to 2011Opportunistic infections--coming to the limits of immunosuppression?Reducing the risk of hepatitis B virus transfusion-transmitted infectionMolecular testing in the diagnosis and management of chronic hepatitis BPHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantationHepatitis B virus infection and transfusion medicine: science and the occult.Diagnostic algorithm for HBV safe transfusion.Sensitivity of individual and mini-pool nucleic acid testing assessed by dilution of hepatitis B nucleic acid testing yield samples.The underlying mechanisms for the "isolated positivity for the hepatitis B surface antigen (HBsAg)" serological profile.Donor-derived infection--the challenge for transplant safety.Surface antigen-negative hepatitis B virus infection in Dutch blood donors.Usefulness of nucleic acid testing to reduce risk of hepatitis B virus transfusion-transmitted infection in Argentina: high rate of recent infections.Total numbers of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age- and area-specific prevalence on the national scale.Detection of occult hepatitis B and window period infection among blood donors by individual donation nucleic acid testing in a tertiary care center in South India.Occult Hepatitis Infection in Transfusion Medicine: Screening Policy and Assessment of Current Use of Anti-HBc TestingVirus NAT for HIV, HBV, and HCV in Post-Mortal Blood Specimens over 48 h after Death of Infected Patients - First Results.Hepatitis B virus nucleic acid amplification testing of Australian blood donors highlights the complexity of confirming occult hepatitis B virus infection.Donor-derived infections in solid organ transplantation.An overview of occult hepatitis B virus infection.Procleix Ultrio transcription-mediated amplification vs. serological blood screening in south-western Greece.The risk of HIV, HBV, HCV and HTLV infection among musculoskeletal tissue donors in Australia.Trends in transfusion-transmissible infections among Australian blood donors from 2005 to 2010.Hepatitis B and residual risk of infection in English and Welsh blood donors, 1996 through 2008.Enhanced detection of hepatitis B virus in Hong Kong blood donors after introduction of a more sensitive transcription-mediated amplification assay.Hepatitis B virus testing by minipool nucleic acid testing: does it improve blood safety?Hepatitis B virus transmission by blood transfusion during 4 years of individual-donation nucleic acid testing in South Africa: estimated and observed window period risk.Sensitivity comparison of two Food and Drug Administration-licensed, triplex nucleic acid test automated assays for hepatitis B virus DNA detection and associated projections of United States yield.The current incidence, prevalence, and residual risk of hepatitis B viral infections among voluntary blood donors in China.Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services.Value of retaining HBsAg donor screening where HBV NAT and anti-HBc donor screening applyGuidelines for the establishment and operation of a donor human milk bank
P2860
Q34147896-1F6EF079-6E1E-416B-8056-14B3A42C0EB5Q34994357-61997389-5FD0-4179-B167-7BD4503A45BFQ35004372-9988C107-9D3B-442A-A6A7-6082C50C6AFCQ35683881-12E613E5-E410-403A-B912-F829F17BC368Q36881140-8E22A155-86A6-4D2E-B8A0-F49B8CD93324Q36909187-B6BCC60B-436C-4E72-8A87-82B7D3702197Q37153782-FC8BEB8D-CA2F-4EE7-A57B-3D3C82473D39Q37284917-5820EBF0-1490-47E0-AF5A-28F4E7241521Q37618608-47F32ED2-BD30-4496-BA5A-3795C1458684Q37748557-756B2432-396D-4DC7-BC90-0C93CD5C5C8EQ38245354-513F63CA-85ED-4BAC-9F6E-03BBEA205F77Q38394324-2C2B4432-9938-451D-B7E6-64DBB6BFB49EQ39131395-E717CB53-4381-4BDB-BCBC-1EEB706ED6FBQ39765312-ADB12F27-8761-4093-90F6-4BDA7F63F2C7Q40479321-0D183359-0851-40AD-9101-93B254E0DF6AQ41111337-0D564E67-3886-478C-A435-778926D13BDEQ41878730-51E27397-982B-4BE1-815B-942E8142420AQ42230165-358AE1FD-A7BA-4FB4-816D-3E88908AA4B9Q42272362-A9F1691C-F5F4-46F0-949B-394C5D91C8F5Q42722415-DA9FA30C-131A-42E2-9A78-6EFDF55288F3Q42977683-83FDF657-4149-4E59-9C95-12CCEAE829F0Q43041881-4E69D475-B252-4D32-ABC9-CEDCEC35C287Q43406238-93DD90F1-BCC5-406E-9D18-A47E130646D8Q43851125-07CC9480-094B-4924-A20D-530E65B48391Q44164538-72C88DF2-4DB0-481B-995A-1221D392F9C7Q45351561-99A5A702-4C9E-4632-9620-C338F204B1E1Q45362712-F9024D71-B8DA-4A48-BD69-8654D5643D83Q45363580-83A2CC9D-30DB-4579-ABFC-C0CF0B3F1B05Q47134046-E2057A97-F649-431A-8B39-E10D848118F8Q48081521-9837B803-DD41-4B06-95EC-940AEF0F6497Q57176158-D755D0AF-EE34-4A39-B360-1B0686C75372Q58801459-79FE2584-DB6E-469A-94C9-0B1103E59DF3
P2860
Assessing the impact of HBV NAT on window period reduction and residual risk.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Assessing the impact of HBV NAT on window period reduction and residual risk.
@ast
Assessing the impact of HBV NAT on window period reduction and residual risk.
@en
type
label
Assessing the impact of HBV NAT on window period reduction and residual risk.
@ast
Assessing the impact of HBV NAT on window period reduction and residual risk.
@en
prefLabel
Assessing the impact of HBV NAT on window period reduction and residual risk.
@ast
Assessing the impact of HBV NAT on window period reduction and residual risk.
@en
P1476
Assessing the impact of HBV NAT on window period reduction and residual risk.
@en
P2093
Steven H Kleinman
P356
10.1016/S1386-6532(06)80005-3
P478
36 Suppl 1
P577
2006-05-01T00:00:00Z